Presentations and Scientific papers

Anne has frequently presented at Scientific conferences and helped to organize such meetings.

Recent conference presentations and publication by Anne B. Tolstrup

Animal Cell Technology in a Nutshell
Bispecifics: Different Formats bring Different Treatment Opportunities
Will Technological Progress in CLD Enable a Faster Track to the Patient?

Alexandra Schulz, Trent Munro, Anja Puklowski, Emma Slack, Kerstin Otte, Anne B. Tolstrup. Systematic review and data-driven insights into CHO cell engineering for next-generation antibody production. MAbs 2026 Jan www.tandfonline.com/doi/full/10.1080/19420862.2026.2615475

Recent scientific papers in the Biotherapeutics field that might be of interest to you

Crescioli S, Kaplon H, Chenoweth A, Wang L, Visweswaraiah J, Reichert JM. Antibodies to watch in 2024. MAbs. 2024 Jan-Dec;16(1):2297450. doi: 10.1080/19420862.2023.2297450. Epub 2024 Jan 5. PMID: 38178784; PMCID: PMC10773713.
Madsen AV, Pedersen LE, Kristensen P, Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotechnol. 2024 Jan 25;12:1352014. doi: 10.3389/fbioe.2024.1352014. PMID: 38333084; PMCID: PMC10850309.
Barnard GC, Zhou M, Shen A, Yuk IH, Laird MW. Utilizing targeted integration CHO pools to potentially accelerate the GMP manufacturing of monoclonal and bispecific antibodies. Biotechnol Prog. 2024 Jan-Feb;40(1):e3399. doi: 10.1002/btpr.3399. Epub 2023 Oct 24. PMID: 37874920.
Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020 May;38(5):540-545. doi: 10.1038/s41587-020-0512-5. PMID: 32317764; PMCID: PMC7173776.
Higgins MF, Abu-Absi N, Gontarz E, Gorr IH, Kaiser K, Patel P, Ritacco F, Sheehy P, Thangaraj B, Gill T. Accelerated CMC workflows to enable speed to clinic in the COVID-19 era: A multi-company view from the biopharmaceutical industry. Biotechnol Prog. 2023 Mar;39(2):e3321. doi: 10.1002/btpr.3321. Epub 2023 Jan 20. PMID: 36546782; PMCID: PMC9880703.
Surowka M, Klein C. A pivotal decade for bispecific antibodies? MAbs. 2024 Jan-Dec;16(1):2321635. doi: 10.1080/19420862.2024.2321635. Epub 2024 Mar 11. Erratum in: MAbs. 2024 Jan-Dec;16(1):2335597. doi: 10.1080/19420862.2024.2335597. PMID: 38465614; PMCID: PMC10936642.
Mizrahi RA, Lin WY, Gras A, Niedecken AR, Wagner EK, Keating SM, Ikon N, Manickam VA, Asensio MA, Leong J, Medina-Cucurella AV, Benzie E, Carter KP, Chiang Y, Edgar RC, Leong R, Lim YW, Simons JF, Spindler MJ, Stadtmiller K, Wayham N, Büscher D, Terencio JV, Germanio CD, Chamow SM, Olson C, Pino PA, Park JG, Hicks A, Ye C, Garcia-Vilanova A, Martinez-Sobrido L, Torrelles JB, Johnson DS, Adler AS. GMP Manufacturing and IND-Enabling Studies of a Recombinant Hyperimmune Globulin Targeting SARS-CoV-2. Pathogens. 2022 Jul 19;11(7):806. doi: 10.3390/pathogens11070806. PMID: 35890050; PMCID: PMC9320065.
Moleirinho MG, Silva RJS, Alves PM, Carrondo MJT, Peixoto C. Current challenges in biotherapeutic particles manufacturing. Expert Opin Biol Ther. 2020 May;20(5):451-465. doi: 10.1080/14712598.2020.1693541. Epub 2019 Nov 27. PMID: 31773998.
Popkin ME, Goese M, Wilkinson D, Finnie S, Flanagan T, Campa C, Clinch A, Teasdale A, Lennard A, Cook G, Mohan G, Osborne MD. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines. AAPS J. 2022 Sep 27;24(6):101. doi: 10.1208/s12248-022-00751-9. PMID: 36168002; PMCID: PMC9514697.
Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021 Apr 6;11(4):69. doi: 10.1038/s41408-021-00459-7. PMID: 33824268; PMCID: PMC8024391.